Skip to main content

Table 2 Genetic polymorphisms in DNA repair genes and survival of patients

From: Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma

Genotype Patients(%) MST(mon) Log-rank P HR(95%CI) Adjusted HR(95%CI)A
ERCC2 Lys751Gln
   AA 194(75.5) 14.50   1.00 1.00
   AC 59(23.0) 10.40 0.10 1.40(1.01-1.94) 1.32(0.95-1.84)
   CC 4(1.5) 12.27   0.73(0.23-2.28) 0.79(0.25-2.48)
   AC/CCB 63(24.5) 10.97 0.08 1.33(0.97-1.82) 1.27(0.92-1.75)
ERCC2 Asp312Asn
   GG 229(89.1) 13.23   1.00 1.00
   GA 27(10.5) 12.40 0.05 0.95(0.60-1.49) 0.95(0.60-1.49)
   AA 1(0.4) 4.40   8.25(1.12-60.60) 8.55(1.14-64.25)
   GA/AAC 28(10.9) 9.83 0.96 0.99(0.63-1.54) 0.99(0.63-1.54)
ERCC1 Asn118Asn
   CC 140(54.5) 17.23   1.00 1.00
   CT 94(36.6) 11.07 < 0.001 1.58(1.18-2.12) 1.48(1.10-1.99)
   TT 23(8.9) 6.20   2.82(1.72-4.62) 2.67(1.62-4.40)
XRCC1 Arg399Gln
   GG 117(45.5) 19.10   1.00 1.00
   GA 102(39.7) 10.40 < 0.001 1.41(1.05-1.91) 1.28(0.95-1.74)
   AA 38(14.8) 9.23   2.33(1.56-3.47) 2.68(1.79-4.02)
  1. Abbreviation: MST, median survival time; HR, hazard ratio; CI, confidence interval.
  2. AHR adjusted for age, stage, surgical operation and chemotherapy or radiotherapy.
  3. BLog-rank P and HR were calculated compared with wild genotype(AA) of ERCC2 751 polymorphism.
  4. CLog-rank P and HR were calculated compared with wild genotype(GG) of ERCC2 312 polymorphism.